What is Fumaria used for?

Fumaria is indicated for General toxicity symptom relief.

Fumaria is developed by Shiraz University of Medical Sciences.

What development phase is Fumaria in?

Fumaria is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Fumaria

Shiraz University of Medical Sciences · FDA-approved active Small molecule Quality 11/100

Fumaria, marketed by Shiraz University of Medical Sciences, is positioned in the general toxicity symptom relief segment. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity and potential market protection. The primary risk lies in the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.

At a glance

Generic name	Fumaria
Sponsor	Shiraz University of Medical Sciences
Drug class	Non-Standardized Food Allergenic Extract [EPC]
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

General toxicity symptom relief

Common side effects

No common side effects on file.

Key clinical trials

Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fumaria CI brief — competitive landscape report
Fumaria updates RSS · CI watch RSS
Shiraz University of Medical Sciences portfolio CI